Verrica Pharmaceuticals (NASDAQ:VRCA) Announces Quarterly Earnings Results

Key Points

• Verrica reported EPS of ($0.51), missing the consensus of ($0.43) by $0.08, while revenue of $5.09 million topped expectations of $4.52 million.
• Shares opened at $5.98, the company has a market cap of $95.62 million and a 1‑year trading range of $3.28–$9.82, with a negative P/E reflecting ongoing losses.
• Analysts are mixed: the average rating is Hold with an average price target of $17.00 (two Buys, three Holds, one Sell), and institutional ownership is about 42.45% as some funds recently added or initiated stakes.

Verrica Pharmaceuticals (NASDAQ:VRCA - Get Free Report) posted its quarterly earnings results on Wednesday. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.08), FiscalAI reports. The business had revenue of $5.09 million for the quarter, compared to analysts' expectations of $4.52 million.

Verrica Pharmaceuticals Price Performance

Shares of NASDAQ VRCA opened at $5.98 on Wednesday. The company has a 50-day moving average price of $6.79 and a 200-day moving average price of $5.86. The stock has a market capitalization of $95.62 million, a P/E ratio of -1.75 and a beta of 1.47. Verrica Pharmaceuticals has a 1 year low of $3.28 and a 1 year high of $9.82.

Analyst Upgrades and Downgrades

VRCA has been the subject of several research reports. Loop Capital set a $17.00 target price on Verrica Pharmaceuticals in a research note on Thursday, December 18th. Brookline Capital Acquisition raised Verrica Pharmaceuticals from a "hold" rating to a "buy" rating and set a $17.00 price target on the stock in a research note on Thursday, December 18th. Wall Street Zen lowered Verrica Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Saturday, February 7th. Zacks Research cut Verrica Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Monday. Finally, TD Cowen restated a "buy" rating on shares of Verrica Pharmaceuticals in a report on Wednesday, January 7th. Two investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average price target of $17.00.

Hedge Funds Weigh In On Verrica Pharmaceuticals

Several large investors have recently added to or reduced their stakes in VRCA. State Street Corp boosted its stake in Verrica Pharmaceuticals by 14.1% during the 4th quarter. State Street Corp now owns 23,481 shares of the company's stock valued at $195,000 after purchasing an additional 2,900 shares during the last quarter. Man Group plc purchased a new stake in shares of Verrica Pharmaceuticals in the fourth quarter worth approximately $94,000. Quadrature Capital Ltd purchased a new stake in shares of Verrica Pharmaceuticals in the fourth quarter worth approximately $99,000. Beck Mack & Oliver LLC bought a new position in shares of Verrica Pharmaceuticals in the fourth quarter valued at approximately $100,000. Finally, Bridgeway Capital Management LLC bought a new position in shares of Verrica Pharmaceuticals in the third quarter valued at approximately $52,000. Institutional investors own 42.45% of the company's stock.

Verrica Pharmaceuticals Company Profile

Verrica Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of topical therapies for dermatological conditions. Its lead investigational product, VP-102, is a standardized formulation of cantharidin in a pre-measured applicator designed to treat molluscum contagiosum and common warts. Verrica's approach emphasizes consistency of dosing and patient convenience, aiming to improve upon off‐label use of existing treatments.

Beyond VP-102, Verrica is advancing VP-103, a next‐generation topical candidate intended to optimize tolerability while maintaining efficacy against viral skin lesions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.